OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
Key Highlights
- ➤Labcorp deal offers $722 million cash plus up to $150 million tied to 4Kscore sales
- ➤Q3 continuing-operations revenue rose 16% to $65.4 million
- ➤Q3 continuing-operations net loss widened to $35.5 million, or $0.05 per share
- ➤OPKO withdrew services-revenue and total-cost guidance amid pending Labcorp transaction
- ➤OPKO dosed first participant in Phase 1/2a trial of OPK-8801001 for acromegaly
MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 and Recent Business Highlights * OPKO enters into agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations. The agreement provides for $722 million in cash consideration at closing, subject to adjustments based on business revenues at closing, and up to $150 million in additional cash consideration over up to ten years based on Labcorp sales of the 4Kscore® test. The transaction remains subject to regulatory approvals and customary closing conditions.
Get started
Create a free account to read the full story.